13 Another study examined 93 trials and found an increased risk of diabetic retinopathy and retinal adverse effects with GLP-1 RA use, though this effect appeared driven by a single agent, albiglutide, which is no longer available
10 These authors found that stimulation of spinal neurokinin 1, NMDA, and non-NMDA receptors enhances spinal release of PGE2, which facilitates the release of spinal amino acids and peptides
Also, being involved in large-scale trials run by the National Institutes of Health and other major organizations taught me how these studies operate and how to contribute within large teams
thus long-term studies are still needed to confirm that the reward-suppressing action can be maintained over time and with repeated GLP-1 analog administration
Below are details regarding their effectiveness in clinical trials
They do this by dialing up how much insulin your body produces and lowering the production of glucagon, a hormone that elevates blood sugar levels